Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Report in relation to renaming Herzog Park set to be withdrawn - 2Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- 3The Best 10 Innovation Developments of the Year
- 4Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer
- 5Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- What's going around right now? COVID, flu, stomach bug on the rise
- Figure out How to Adjust Your Handshake to Various Societies
- 'People We Meet on Vacation' is the 1st of many Emily Henry adaptations: What other books turned movies to look forward to
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- Discovering a true sense of harmony: Contemplation and Care Practices
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- Southern Californians, your health insurance costs could rise in 2026
- Figure out how to Detect the Best Rooftop Substitution Choices
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
